Search Results - "Ready, Joanna"

A chronic hepatitis B identification and surveillance program improves care in an integrated health plan by Chai, Krisna P, Saxena, Varun, Seo, Suk, Horton, Brandon H, Avins, Andrew L, Sedki, Mai, Ready, Joanna B

“…Optimal management of patients with chronic hepatitis B (CHB) requires surveillance for hepatocellular carcinoma (HCC) and identification of antiviral-therapy…”
Get full text

Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists by Pauly, Mary Patricia, Tucker, Lue-Yen, Szpakowski, Jean-Luc, Ready, Joanna B., Baer, David, Hwang, Jessica, Lok, Anna S.-F.

“…Tumor necrosis factor (TNF) antagonists are the first-line treatment for many autoimmune diseases. However, they have been associated with reactivation of…”
Get full text

Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care Setting by Sarkar, Monika, Shvachko, Valentina A., Ready, Joanna B., Pauly, Mary Pat, Terrault, Norah A., Peters, Marion G., Manos, M. Michele

“…Background Few population-based studies have described characteristics and management of patients with chronic hepatitis B (CHB) in the USA. Methods We…”
Get full text

Comparing the Risk of Poor Outcomes Among Hepatitis C–Infected, Cured, and Never-Infected Controls by Saxena, Varun, Wu, Weilu, Balasubramanian, Sreepriya, Mukhtar, Nizar, Seo, Suk I., Ready, Joanna B., MacDonald, Brock A., Schmittdiel, Julie A.

“…Studies show decreased rates of poor outcomes after hepatitis C virus (HCV) cure. However, there are no data comparing risk of poor outcomes to that of HCV…”
Get full text

Serum Fibrosis Marker Panels FIB-4 Index and Aspartate Aminotransferase (AST)-to-Platelet Ratio Index (APRI) Are Equivalent to AST Alone at Predicting Liver Fibrosis in a Cohort of 1731 Patients Infected with Hepatitis C Virus by Drees, Julia C, Wi, Soora, Ready, Joanna B, Dlott, Richard S, Fetterman, Barbara J, Seo, Suk I, Pat Pauly, Mary, Petrie, Matthew S, Lorey, Thomas S

“…Efficient tools are needed to stage liver disease before treatment of patients infected with hepatitis C virus (HCV). Compared to biopsy, several studies…”
Get full text

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis by Saxena, Varun, Nyberg, Lisa, Pauly, Marypat, Dasgupta, Aditi, Nyberg, Anders, Piasecki, Barbara, Winston, Bradley, Redd, Jacquelyn, Ready, Joanna, Terrault, Norah A.

“…Risks and benefits of simeprevir plus sofosbuvir (SIM+SOF) in patients with advanced cirrhosis are unknown. We assessed the safety and sustained virological…”
Get full text

S1202 Demographics of Patients With Chronic Hepatitis B in an Integrated Care System by Sedki, Mai, Horton, Brandon, Avins, Andrew, Corley, Douglas, Chai, Krisna, Ready, Joanna

Get full text

A predictive model for mortality within one year of liver transplantation at the time of wait-listing for transplant: a novel approach using machine learning algorithms in a large US multi-ethnic cohort by Balasubramanian, Sripriya, Bhatnagar, Megha, Wang, Jian, Edelman, Lisa, Valencia, Malou, Rosenberger, Aaron, Freed, Robert, Sahota, Amandeep, Saxena, Varun, Mukhtar, Nizar, Seo, Suk, McDonald, Brock, Ready, Joanna

Get full text

531: DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B WITHIN A LARGE, REPRESENTATIVE, NORTHERN CALIFORNIA COHORT by Saxena, Varun, Liu, Liyan, Ready, Joanna B., Sedki, Mai, Chai, Krisna P., Seo, Suk I., Mukhtar, Nizar A., Balasubramanian, Sreepriya, Macdonald, Brock A., Mehta, Neil, Schmittdiel, Julie A.

Get full text

Mo1579 PREDICTING 30 DAY READMISSION FOLLOWING LIVER TRANSPLANTATION AT WAITLISTING IN PATIENTS WITHOUT HEPATOCELLULAR CARCINOMA: AN INNOVATIVE MACHINE LEARNING APPROACH by Balasubramanian, Sreepriya, Bhatnagar, Megha Sharad, Wang, Jian, Edelman, Lisa, Valencia, Malou, Rosenberger, Aaron, Freed, Robert, Bui, Hien T., Mukhtar, Nizar A., Sahota, Amandeep K., Saxena, Varun, Macdonald, Brock A., Seo, Suk I., Ready, Joanna B.

Get full text

442 PREDICTING INDIVIDUALS WITH HEPATITIS C VIRUS CURE WHOSE RISK OF CIRRHOSIS, DECOMPENSATED CIRRHOSIS OR MORTALITY APPROACHES THE GENERAL POPULATION: IMPLICATIONS FOR WHO CAN SAFELY BE DISCHARGED FROM SPECIALTY CLINIC by Balasubramanian, Sreepriya, Wu, Weilu, Seo, Suk I., Ready, Joanna B., Macdonald, Brock A., Mukhtar, Nizar A., Saxena, Varun, Schmittdiel, Julie A.

Get full text

17 PREDICTING INDIVIDUALS WITH HEPATITIS C VIRUS CURE WHOSE RISK OF HEPATOCELLULAR CARCINOMA APPROACHES THE GENERAL POPULATION: IMPLICATIONS FOR WHO CAN SAFELY BE DISENROLLED FROM HEPATOCELLULAR CARCINOMA SURVEILLANCE PROTOCOLS by Mukhtar, Nizar A., Wu, Weilu, Ready, Joanna B., Seo, Suk I., Macdonald, Brock A., Balasubramanian, Sreepriya, Saxena, Varun, Schmittdiel, Julie A.

Get full text

Prevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017 by Seo, Suk, Silverberg, Michael J., Hurley, Leo B., Ready, Joanna, Saxena, Varun, Witt, David, Hare, C. Bradley, Champsi, Jamila H., Korn, Daniel G., Pauly, Mary Patricia, Chamberland, Scott, Lai, Jennifer B., Marcus, Julia L.

“…Strategic planning for hepatitis C virus (HCV) screening and treatment requires up-to-date information on the prevalence of HCV spontaneous clearance…”
Get full text

EP1003: EVALUATION OF SOCIOECONOMIC STATUS WITHIN HOTSPOTS OF HEPATOCELLULAR CARCINOMA AMONG A LARGE DIVERSE PATIENT COHORT IN NORTHERN CALIFORNIA by Yilma, Mignote, Voelkel, Jackson, Xu, Richie Houhong, Tucker, Leu-Yen, Muzzin, Monica, Saxena, Varun, Mehta, Neil, Lee, Jeffrey K., Seo, Suk I., Macdonald, Brock A., Ready, Joanna B., Balasubramanian, Sreepriya, Mukhtar, Nizar A.

Get full text

Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals by Lam, Jennifer O, Hurley, Leo B, Lai, Jennifer B, Saxena, Varun, Seo, Suk, Chamberland, Scott, Quesenberry, Jr, Charles P, Champsi, Jamila H, Ready, Joanna, Chiao, Elizabeth Y, Marcus, Julia L, Silverberg, Michael J

“…Chronic hepatitis C virus (HCV) infection is a leading cause of liver cancer. The association of HCV infection with extrahepatic cancers, and the impact of…”
Get full text

Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System by Lai, Jennifer B., Witt, Maxwell A., Pauly, Mary Patricia, Ready, Joanna, Allerton, Michael, Seo, Suk, Witt, David J.

“…Background Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of…”
Get full text

Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population by Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Pat, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk I., Witt, David J., Silverberg, Michael J.

“…Objectives: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data…”
Get full text

No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients by Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Patricia, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk I., Witt, David J., Silverberg, Michael J.

“…Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1…”
Get full text

Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system by Lam, Jennifer O, Hurley, Leo B, Chamberland, Scott, Champsi, Jamila H, Gittleman, Laura C, Korn, Daniel G, Lai, Jennifer B, Quesenberry, Jr, Charles P, Ready, Joanna, Saxena, Varun, Seo, Suk I, Witt, David J, Silverberg, Michael J, Marcus, Julia L

“…U.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with…”
Get more information

A Little Help from Our Friends: Intra-operative Endoscopy for the Extraction of an Ingested Foreign Body by Barreto-Chang, Odmara, Palmer, Owen, Ready, Joanna, Hwang, Jemmy

Get full text